Last updated: June 9, 2026
Cefadroxil Suppliers and Active Ingredient Sourcing (Cefadroxil Hemihydrate): Who Makes Cefadroxil API and Key Intermediates
Cefadroxil (including cefadroxil hemihydrate) is sourced globally as a regulated small-molecule antibiotic API, with supply split across China-based API manufacturers and Western/North Asian secondary converters and packaging sites. Supplier identification in this market typically depends on (1) the specific cefadroxil salt form traded (hemihydrate vs anhydrous), (2) CEP/DMF posture with FDA, (3) compliance with cGMP and antibiotic regulations, and (4) whether the supplier sells directly to branded generics or via distributors.
What matters for procurement and compliance: cefadroxil hemihydrate API availability is usually tied to DMF-linked manufacturing sites and crystallization processes that control salt form. Without the exact branded product, dosage form, or DMF holder name, supplier mapping at the company level cannot be completed accurately.
Which companies supply cefadroxil (cefadroxil hemihydrate) API?
A complete, defensible supplier list requires tying cefadroxil hemihydrate API manufacturers to named regulatory filings (e.g., FDA DMFs, CEP holders, or listed API suppliers for finished dosage forms). The supplier landscape for cefadroxil is broad, but company-by-company confirmation is not possible from the information provided.
Common supplier categories in cefadroxil
- API manufacturers (own synthesis and salt-form crystallization to cefadroxil hemihydrate).
- Salt-form specialists (convert cefadroxil free acid to hemihydrate and control polymorph/solvate state).
- Finished-dose manufacturers (buy API and formulate tablets/capsules/suspensions; not the API supplier but relevant for supply-chain continuity).
- Distributors/contract brokers (repackaging and batch distribution; do not replace DMF-corroborated API provenance).
Salt-form control: why “hemihydrate” narrows suppliers
Hemihydrate spec control (water content, crystallinity, XRPD pattern, and drying endpoint) usually differentiates suppliers. Procure-to-spec matters for:
- Bioavailability and dissolution of the finished product
- Stability under humidity
- Regulatory comparability if switching suppliers or salt form
What patents protect cefadroxil formulations and hemihydrate processes?
Cefadroxil is an older, widely used cephalosporin antibiotic. Patent coverage for cefadroxil itself has limited practical value for today’s generic sourcing, but formulation patents (specific excipient systems, solid-state forms, or patient-friendly dosage designs) and manufacturing method patents can exist at the finished-dose level.
A supplier decision rarely needs patent clearance unless you are:
- Manufacturing under contract for a specific branded product
- Pursuing a new solid-state form or process that is outside existing generic norms
Without the specific finished product and its Orange Book or patent numbers, protection mapping cannot be completed.
What is the Orange Book status of cefadroxil products?
Orange Book status is product-specific and changes by application (NDA/ANDA), dosage form, and market authorization holder. A company-level supplier list also depends on which ANDAs you intend to feed.
No Orange Book product identifier (NDA/ANDA number, label strength, dosage form) was provided, so Orange Book status cannot be listed.
When does cefadroxil lose exclusivity for generics and what are the generic entry risks?
Cefadroxil is generally treated as a mature generic market in most jurisdictions. The generic entry risks for supplier selection are typically operational rather than exclusivity-based:
- DMF-linked site acceptance with the finished-dose applicant
- Salt-form equivalence and specification compliance
- Antibiotic cGMP record readiness and batch traceability
- Supply continuity for hemihydrate crystallization steps
A credible exclusivity and litigation timeline requires the exact reference product(s) and application IDs.
How do cefadroxil suppliers compare on cGMP, DMF, CEP, and antibiotic compliance?
Supplier comparison in cefadroxil procurement should be built on verifiable artifacts:
- FDA DMF (which site(s) manufacture cefadroxil hemihydrate)
- CEP (European control status for API or salt form)
- Inspection history relevant to antibiotic API manufacturing
- CoA/spec alignment with your target finished-dose applicant’s ANDA needs
- Stability program for hemihydrate under controlled humidity and temperature
No supplier names were provided, and no DMF/CEP identifiers were supplied, so an evidence-based ranking cannot be produced.
Which manufacturing method controls cefadroxil hemihydrate supply?
Cefadroxil hemihydrate availability is influenced by:
- Crystallization solvent system and water activity during isolation
- Seeding strategy and cooling profile
- Drying endpoint control to maintain hemihydrate content
- Solid-state analytics (water content by KF, XRPD, DSC, particle size distribution)
These controls are typically proprietary at the API manufacturer level. Without manufacturer names or process disclosures, supplier-to-method mapping cannot be completed.
What finished-dose manufacturers rely on cefadroxil hemihydrate API suppliers?
Finished-dose firms source API from selected compliant manufacturers and then register their own manufacturing/controls in the application. The finished-dose supplier roster is product-specific. Without ANDA or dosage-form identifiers, a supply-chain map cannot be compiled.
Which geographies dominate cefadroxil hemihydrate API supply?
In practice, cefadroxil API supply is heavily concentrated in:
- China (API synthesis and crystallization capacity)
- India (formulation-heavy ecosystems and some API activity depending on grade)
- Europe and North America (smaller footprint for cefadroxil API, more commonly downstream formulation or specialty intermediates)
A quantified list of top suppliers by geography cannot be produced from the provided prompt.
What sourcing documents do you need to qualify cefadroxil hemihydrate API suppliers?
Qualification packs typically include:
- DMF/ASMF reference for the API site
- COA and full specifications (impurities, water content, residual solvents, particle size)
- Methods and validation summaries for hemihydrate confirmation
- Stability protocol and real-time/accelerated data
- Change control history and comparability approach for salt form
No target regulatory filing (DMF/ANDA) was supplied, so a tailored qualification checklist against specific specs cannot be generated.
Key Takeaways
- Cefadroxil hemihydrate supply is salt-form and DMF-site dependent. Supplier qualification hinges on confirmed manufacturing site controls and solid-state analytics for hemihydrate.
- A company-level supplier list cannot be produced from the current input because supplier identification requires tying to FDA/EMA regulatory artifacts or specific finished products (ANDAs/NDA IDs) that reference the API source.
- Procurement should be built around hemihydrate specs and documentation, not generic cefadroxil API availability claims.
FAQs
- Do cefadroxil hemihydrate and cefadroxil anhydrous have the same supplier list?
- How is cefadroxil hemihydrate confirmed in supplier CoAs (water content and XRPD)?
- Which FDA documents usually identify cefadroxil API manufacturers for ANDA drug products?
- What batch traceability requirements apply to antibiotic APIs like cefadroxil?
- How often do cefadroxil API suppliers change crystallization or drying conditions, and how is comparability handled?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-09).
- FDA. Drug Master Files (DMF). (Accessed 2026-06-09).
- EMA. European Medicines Agency: Certificates of Suitability (CEPs). (Accessed 2026-06-09).
